Known targets — ChEMBL curated mechanism
COXFA4COXFA4L2GPD2MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3
The experimentally established mechanism targets of Metformin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metformin SCHEMBL8944 | 1.00 | — | — | |
| Metformin SCHEMBL1333960 | 0.97 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL22127017 | 0.97 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL18953625 | 0.97 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL4421557 | 0.97 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL433864 | 0.97 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL1290484 | 0.97 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL1560020 | 0.97 | LMNA (0.35) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL15268394 | 0.97 | HTT (0.39) | LMNADPP4ADRA1AHTT | |
| Metformin SCHEMBL292820 | 0.97 | LMNA (0.35) | LMNADPP4ADRA1AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015183794-A1 | TGR5 AGONIST COMPLEXES FOR TREATING DIABETES AND CANCER | CITY OF HOPE (US) | 2015-12-03 | — | — | WO | claimed |
| CN-112316013-A | Composition containing guava and tylophora fruits and application thereof | 暨南大学 | 2021-02-05 | — | — | CN | disclosed |
| CN-112316028-A | Composition containing Bordeaux mixture and mulberry leaves and application thereof | 暨南大学 | 2021-02-05 | — | — | CN | disclosed |
| CN-110693867-A | Compositions and methods for treating metabolic disorders | 埃尔舍利克斯治疗公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-105101956-B | Delayed release compositions comprising biguanides | 埃尔舍利克斯治疗公司 | 2018-12-07 | — | — | CN | disclosed |
| EP-3393461-A1 | GROWTH DIFFERENTIATION FACTOR 15 AS BIOMARKER FOR METFORMIN | Sanofi-Aventis Deutschland GmbH (DE) | 2018-10-31 | — | — | EP | disclosed |
| US-20180064662-A1 | NOVEL COMPOSITIONS AND USES OF METFORMIN AGENTS | THE GENERAL HOSPITAL CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| US-9770422-B2 | Compositions and methods for treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
| WO-2017108941-A1 | GROWTH DIFFERENTIATION FACTOR 15 AS BIOMARKER FOR METFORMIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2017-06-29 | — | — | WO | disclosed |
| US-20170165209-A1 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk | ANJI PHARMACEUTICALS INC. | 2017-06-15 | — | — | US | disclosed |
| CN-102906077-A | Use of metformin in combination with glucokinase activator and compositions comprising metformin and glucokinase activator | TRANSTECH PHARMA INC | 2013-01-30 | — | — | CN | disclosed |
| CN-102762209-A | Pharmaceutical composition comprising metformin and rosuvastatin | BCWORLD PHARM CO LTD | 2012-10-31 | — | — | CN | disclosed |
| CN-102549143-A | Extracellular vesicles derived from gram-positive bacteria, and use thereof | AEON MEDIX INC | 2012-07-04 | — | — | CN | disclosed |
| US-20110124022-A1 | METHODS FOR DETECTING PRE-DIABETES AND DIABETES | DIABETOMICS, LLC (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2011051974-A1 | METFORMIN AND A-AMINO ACIDS | NUTRACRYST THERAPEUTICS PRIVATE LIMITED (IN) | 2011-05-05 | — | — | WO | disclosed |
| WO-2009021113-A1 | METHODS FOR ENHANCING GLUTAHIONE PEROXIDASE ACTIVITY | HOLTZMAN, JORDAN, L. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2005117861-A1 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005046675-A2 | METHODS FOR ENHANCING GLUTATHIONE PEROXIDASE ACTIVITY | HOLTZMAN JORDAN (US) | 2005-05-26 | — | — | WO | disclosed |
| EP-1248604-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | Novartis AG (CH) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001052825-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064662-A1 | NOVEL COMPOSITIONS AND USES OF METFORMIN AGENTS | COL2A1, COL1A1, MMP1 | LMNA 1797/4885DPP4 53/4885ADRA1A 1873/4885 |
| US-20170165209-A1 | Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk | PCSK9, HMGCR, PCSK7 | LMNA 412/4885DPP4 20/4885ADRA1A 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.